Table 1. Baseline cohort demographics, disease features, traditional lipids and PON1 activity by treatment group.
| TNFi (n=427) | RTX (n=116) | ABA (n=374) | TCZ (n=296) | P value | |
| Age (years) | 55.3 (12.8) | 58.0 (12.1) | 58.7 (12.6) | 57.6 (12.9) | 0.001* |
| Female | 326 (76.5) | 90 (77.6) | 295 (78.9) | 247 (83.4) | 0.14 |
| Caucasian % | 340 (79.6) | 96 (82.8) | 305 (81.6) | 258 (87.2) | 0.4 |
| BMI (kg/m2) | 29.9 (7.1) | 30.7 (7.5) | 30.3 (6.8) | 30.5 (7.5) | 0.6 |
| Disease duration (years) | 5.0 (7.0) | 12.2 (8.4) | 9.7 (9.6) | 11.7 (9.4) | 0.0001* |
| Seropositive (RF or CCP) | 317 (74.4) | 89 (76.7) | 255 (68.2) | 188 (63.5) | 0.01* |
| Swollen joint count | 8.1 (5.7) | 8.2 (4.8) | 7.6 (5.3) | 7.7 (5.6) | 0.47 |
| Tender joint count | 11.3 (7.3) | 11.9 (7.6) | 10.9 (7.0) | 11.9 (7.7) | 0.28 |
| C reactive protein (mg/L) | 11.6 (20.7) | 7.9 (13.5) | 8.1 (12.5) | 11.7 (17.8) | 0.005* |
| CDAI | 29.7 (13.5) | 31.0 (12.0) | 28.5 (12.1) | 30.4 (12.9) | 0.14 |
| DAS28-CRP | 4.9 (1.1) | 4.9 (1.0) | 4.7 (1.1) | 5.0 (1.1) | 0.01* |
| HAQ | 1.0 (0.7) | 1.1 (0.6) | 1.0 (0.7) | 1.1 (0.7) | 0.01* |
| Current smokers | 101 (24.5) | 18 (15.5) | 61 (16.5) | 36 (12.2) | 0.0003* |
| History of HTN | 100 (23.4) | 35 (30.1) | 131 (35.0) | 86 (29.0) | 0.004* |
| Diabetes mellitus | 41 (9.6) | 7 (6.0) | 35 (9.3) | 38 (12.8) | 0.17 |
| Cholesterol-lowering agents | 96 (22.5) | 33 (28.4) | 107 (28.6) | 80 (27.0) | 0.2 |
| Biologic-naïve | 427 (100.0) | 2 (1.7) | 93 (24.9) | 2 (0.7) | 0.0001* |
| Prednisone use | 135 (31.6) | 39 (33.6) | 130 (34.8) | 89 (30.1) | 0.6 |
| TC (mg/dL)† | 189.9 (40.0) | 191.7 (42.3) | 193.5 (41.1) | 196.8 (39.0) | 0.2 |
| LDL (mg/dL)† | 111.6 (35.5) | 110.9 (35.9) | 113.8 (36.3) | 113.6 (34.9) | 0.8 |
| HDL (mg/dL)† | 60.9 (18.8) | 63.3 (21.5) | 61.0 (17.9) | 62.8 (18.7) | 0.4 |
| TG (mg/dL)† | 141.0 (84.3) | 142.1 (92.7) | 151.8 (86.3) | 161.3 (99.2) | 0.02* |
| PON (U/mL) | 679.6 (497.9) | 648.0 (428.8) | 639.7 (497.1) | 660.4 (473.9) | 0.6 |
| LAC (U/mL) | 23.9 (8.5) | 24.6 (7.8) | 23.6 (8.3) | 24.3 (7.8) | 0.4 |
| ARYL (U/mL) | 253.9 (71.4) | 250.1 (70.5) | 249.4 (74.6) | 254.6 (67.4) | 0.5 |
Values are mean (SD), n (%), and represent those of the baseline visit.
Significance testing by one-way ANOVAanalysis of variance for continuous variables, and Chi-squaredχ2 testing for categorical variables.
Significance testing on PON/LAC/ARYL performed on Llog10 transformed data.
LDL was measured and not calculated.
P<0.05.
All lipids were measured prospectively in a central laboratory.
ARYL, arylesterase activity; BMIbody mass indexCCP, anticyclic citrullinated peptide antibody; CDAIClinical Disease Activity IndexCRPC reactive proteinDAS28Disease Activity Score 28HAQHealth Assessment QuestionnaireHDL, high-density lipoprotein; HTN, hypertension; LAC, lactonase activityLDL, low-density lipoprotein; PON, paraoxonase activity; RF, rheumatoid factor; TC, total cholesterol; TG, triglyceridesTNFitumour necrosis factor inhibitors